Diabetes control: Incidence of acute myocardial infarction and all-cause mortality among patients with 3

Abstract

Background

Optimal glycated haemoglobin (HbA1c) concentrations to minimize large vessel complications and prolong life in diabetes patients are not well established.

Design

A retrospective cohort study from 2010 to 2012 using data from the Clalit Health Service (Clalit) integrated healthcare system’s electronic data warehouse. Patients included had newly incident diabetes, had at least two HbA1c measurements during the 3 years prior to 1 January 2010 without any disruption(s) in Clalit membership between 2010 and 2014.

Methods

Time-dependent variables were utilized for HbA1c concentration exposure at three time periods. Diabetes control was evaluated taking average HbA1c measures per time period. Unadjusted and adjusted extended Cox regression analyses assessed the association between time-dependent average HbA1c level and acute myocardial infarction and all-cause mortality.

Results

Among our 61,971 participants, 2.0% experienced acute myocardial infarction and 6.9% died. Compared to patients with HbA1c 7.0 to < 7.5%, a higher risk of myocardial infarction was found with 8.5 to < 9.0% (hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.05–1.91) and ≥9.0% (HR 1.87, 95% CI 1.50-2.33) groups; a lower risk was found among <6.0% (HR 0.74, 95% CI 0.59–0.93), 6.0 to < 6.5% (HR 0.77, 95% CI 0.64–0.94) and 6.5 to < 7.0% (HR 0.73, 95% CI 0.60–0.88) groups. The association with all-cause mortality was J-shaped, demonstrating a higher risk in those <6.0% (HR 1.20, 95% CI 1.06–1.34), 7.5 to < 8.0% (HR 1.17, 95% CI 1.02–1.35), 8.0 to < 8.5% (HR 1.38, 95% CI 1.16–1.64), 8.5 to < 9.0% (HR 1.36, 95% CI 1.10–1.67) and ≥9.0% (HR 1.74, 95% CI 1.49–2.04) groups.

Conclusions

HbA1c concentration below 6.0% may be associated with an excess risk for all-cause mortality. Clinicians must be aware of this association when treating individual patients.

Keywords

Diabetes mortality glycated haemoglobin myocardial infarction

Get full access to this article

View all access options for this article.

References

Nedkoff

Knuiman

Hung

. Long-term all-cause and cardiovascular mortality following incident myocardial infarction in men and women with and without diabetes: temporal trends from 1998 to 2009. Eur J Prev Cardiol 2016; 23: 1273–1281.

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.

Patel

MacMahon

Chalmers

. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572.

Duckworth

Abraira

Moritz

. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–139.

Gerstein

Miller

Byington

. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.

Skyler

Bergenstal

Bonow

. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32: 187–192.

Stratton

Adler

Neil

. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–412.

10.

Nichols

Joshua-Gotlib

Parasuraman

. Glycemic control and risk of cardiovascular disease hospitalization and all-cause mortality. J Am Coll Cardiol 2013; 62: 121–127.

11.

Zoungas

Chalmers

Ninomiya

. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012; 55: 636–643.

12.

Colayco

Niu

McCombs

. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 2011; 34: 77–83.

13.

Currie

Peters

Tynan

. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481–489.

14.

Chamnan P, Simmons RK, Khaw KT, et al. Change in HbA1c over 3 years does not improve the prediction of cardiovascular disease over and above HbA1c measured at a single time point. Diabetologia 2013; 56: 1004–1011.

15.

Eeg-Olofsson

Cederholm

Nilsson

. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 2010; 268: 471–482.

16.

Paprott

Schaffrath Rosario

Busch

. Association between hemoglobin A1c and all-cause mortality: results of the mortality follow-up of the German National Health Interview and Examination Survey 1998. Diabetes Care 2015; 38: 249–256.

17.

Chen YY, Lin YJ, Chong E, et al. The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: A representative cohort study in Taiwan. PLoS ONE 2015; 10: e0123116.

18.

Arnold LW and Wang Z. The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: A meta-analysis of observational studies. Rev Diabet Stud 2014; 11: 138–152.

19.

Anand

Dagenais

Mohan

. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol 2012; 19: 755–764.

20.

Kowalczyk

Mazurek

Zielinska

. Prognostic significance of HbA1c in patients with AMI treated invasively and newly detected glucose abnormalities. Eur J Prev Cardiol 2015; 22: 798–806.

21.

Duckworth

Abraira

Moritz

. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications 2011; 25: 355–361.

22.

Brown

Reynolds

Bruemmer

. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 2010; 7: 369–375.

23.

Rodríguez-Gutiérrez

Montori

. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes 2016; 9: 504–512.

24.

Karpati

Cohen-Stavi

Leibowitz

. Towards a subsiding diabetes epidemic: trends from a large population-based study in Israel. Popul Health Metr 2014; 12: 32–32.

25.

Johns Hopkins Bloomberg School of Public Health, The Johns Hopkins University. The Johns Hopkins ACG System: Version 11.0 Technical Reference Guide; 2014.

26.

Israeli Central Bureau of Statistics. Characterization and Classification of Local Authorities by the Socio-Economic Level of the Population 2003. Israel: Israeli Bureau of Statistics. 2006. www.cbs.gov.il/www/publications/local_authorities2003/local_authorities_e.htm (accessed 22 May 2016).

27.

Singer

Hoshen

Shadmi

. EMR-based medication adherence metric markedly enhances identification of nonadherent patients. Am J Manag Care 2012; 18: e372–e377.

28.

Yahagi K, Kolodgie FD, Lutter C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol 2016; 37: 191–204.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.63 MB

Diabetes control: Incidence of acute myocardial infarction and all-cause mortality among patients with 3–6 years’ disease duration